These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2138629)

  • 21. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
    Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
    J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis).
    Scharla SH; Minne HW; Lempert UG; Leidig G; Hauber M; Raedsch R; Ziegler R
    Exp Clin Endocrinol; 1994; 102(1):44-9. PubMed ID: 8005208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral and related biochemical variables in patients with Kock ileal reservoir or Bricker conduit for urinary diversion.
    Campanello A; Herlitz H; Lindstedt G; Mellström D; Wilske J; Akerland S; Jonsson O
    J Urol; 1996 Apr; 155(4):1209-13. PubMed ID: 8632532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone mineral density in patients with growth hormone deficiency: does a gender difference exist?
    Hitz MF; Jensen JE; Eskildsen PC
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):783-91. PubMed ID: 17121531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased serum osteocalcin levels in elderly females with vitamin D deficiency.
    Pietschmann P; Woloszczuk W; Pietschmann H
    Exp Clin Endocrinol; 1990 Apr; 95(2):275-8. PubMed ID: 2365024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
    Moghetti P; Castello R; Zamberlan N; Rossini M; Gatti D; Negri C; Tosi F; Muggeo M; Adami S
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.
    Johansen JS; Riis BJ; Hassager C; Moen M; Jacobson J; Christiansen C
    J Clin Endocrinol Metab; 1988 Oct; 67(4):701-6. PubMed ID: 2971080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.
    Young NR; Baker HW; Liu G; Seeman E
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1028-32. PubMed ID: 8408450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.
    Mitlak BH; Williams DC; Bryant HU; Paul DC; Neer RM
    J Bone Miner Res; 1992 May; 7(5):479-84. PubMed ID: 1615756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
    Carmina E; Janni A; Lobo RA
    J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study.
    Khosla S; Atkinson EJ; Melton LJ; Riggs BL
    J Clin Endocrinol Metab; 1997 May; 82(5):1522-7. PubMed ID: 9141544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.
    Lu KC; Shieh SD; Chyr SH; Lin SH; Li BL; Diang LK; Chen WQ; Lin YF
    Diabetes Res; 1993; 22(3):97-104. PubMed ID: 8076446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.
    Ahmad AM; Thomas J; Clewes A; Hopkins MT; Guzder R; Ibrahim H; Durham BH; Vora JP; Fraser WD
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2860-8. PubMed ID: 12788900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F; Nieves J; Shen V; Lindsay R
    J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cortical remodeling following suppression of endogenous estrogen with analogs of gonadotrophin releasing hormone.
    Bell KL; Loveridge N; Lindsay PC; Lunt M; Garrahan N; Compston JE; Reeve J
    J Bone Miner Res; 1997 Aug; 12(8):1231-40. PubMed ID: 9258753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
    Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.